Sepsis

Christopher Slachta Joins Cytovale as Chief Operating Officer

Retrieved on: 
Monday, March 4, 2024

SAN FRANCISCO, March 4, 2024 /PRNewswire/ -- Cytovale®, a commercial-stage medical diagnostics company focused on advancing early detection technologies to diagnose fast-moving and immune-mediated diseases, today announced the appointment of Christopher Slachta, Ph.D., MBA, as the company's chief operating officer (COO). With more than 20 years of experience in the medical device and diagnostic industry, Slachta will lead operations as Cytovale ramps up production of its FDA-cleared rapid sepsis diagnosis test — IntelliSep®.

Key Points: 
  • SAN FRANCISCO, March 4, 2024 /PRNewswire/ -- Cytovale ® , a commercial-stage medical diagnostics company focused on advancing early detection technologies to diagnose fast-moving and immune-mediated diseases, today announced the appointment of Christopher Slachta, Ph.D., MBA, as the company's chief operating officer (COO).
  • With more than 20 years of experience in the medical device and diagnostic industry, Slachta will lead operations as Cytovale ramps up production of its FDA-cleared rapid sepsis diagnosis test — IntelliSep ® .
  • Slachta joins Cytovale after serving 12 years at Abbott, most recently as divisional vice president of global operations and supply chain, molecular diagnostics.
  • Ajay and his team have developed a proven solution with the potential to make a huge clinical impact on patient care," said Slachta.

Vivacelle Bio and University of Missouri-Kansas City School of Medicine Announce Groundbreaking Results from Phase 2a Clinical Trial of VBI-S for Refractory Hypotension in Severe Septic Shock Patients

Retrieved on: 
Thursday, February 29, 2024

This landmark study now published in the Lancet's eClinicalMedicine , showcases the potential of VBI-S in transforming the treatment landscape for refractory hypotension in these critically ill patients.

Key Points: 
  • This landmark study now published in the Lancet's eClinicalMedicine , showcases the potential of VBI-S in transforming the treatment landscape for refractory hypotension in these critically ill patients.
  • Patients, after failing standard fluids, received intravenous VBI-S, a revolutionary composition of phospholipid nanoparticles that reversibly absorb nitric oxide.
  • These results fuel our optimism that at last we may have an effective and safe intervention for these very sick patients."
  • This groundbreaking research opens new possibilities for the treatment of septic shock, offering hope and potential survival for millions of patients worldwide.

Asep Medical's Sepsis Diagnostic Technology Can Provide Improved Odds for Pediatric Appendicitis

Retrieved on: 
Tuesday, February 27, 2024

VANCOUVER, BC, Feb. 27, 2024 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is pleased to announce that its proprietary gene expression signature for sepsis can provide an improved assessment of the severity of appendicitis in children.

Key Points: 
  • VANCOUVER, BC, Feb. 27, 2024 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is pleased to announce that its proprietary gene expression signature for sepsis can provide an improved assessment of the severity of appendicitis in children.
  • The study found that the "diagnostic study of 71 patients with pediatric appendicitis using systems immunology methods revealed a mechanistic understanding of severe disease, indicating immune dysregulation similar to that observed in sepsis.
  • The study concluded that early diagnostics and management strategies for pediatric PA should be informed by underlying immune dysregulation and similarities to sepsis.
  • Based on the new potential benefits of this ER technology, we look forward to improving outcomes for children presenting with abdominal pain in the ER."

JOURNEY OF A GERM: New study reveals backpacks can harbor hundreds of thousands of germs

Retrieved on: 
Tuesday, February 27, 2024

"They move among people and on surfaces, sometimes causing illnesses that could impact our families or impact our daily activities.

Key Points: 
  • "They move among people and on surfaces, sometimes causing illnesses that could impact our families or impact our daily activities.
  • Items we least suspect can often be culprits for spreading germs, as shown by our study."
  • Backpacks were chosen to represent how similar everyday items can be responsible for transmitting germs.
  • The backpacks came into contact with a surface for about two minutes, three times a day for two days.

SafeDose Adds Pediatric Education Resources to its Acute Care Medication Safety Software

Retrieved on: 
Tuesday, February 27, 2024

SOUTHBOROUGH, Mass., Feb. 27, 2024 /PRNewswire-PRWeb/ -- SafeDose®, a pioneer in the safe, simple, and standardized delivery of pediatric medication in acute care settings, has added a comprehensive set of educational tools which can be used to train nurses who care for pediatric patients in emergency settings. The Pediatric Education Resources package is included with the Premium subscription offering for the SafeDose drug administration software suite.

Key Points: 
  • SOUTHBOROUGH, Mass., Feb. 27, 2024 /PRNewswire-PRWeb/ -- SafeDose®, a pioneer in the safe, simple, and standardized delivery of pediatric medication in acute care settings, has added a comprehensive set of educational tools which can be used to train nurses who care for pediatric patients in emergency settings.
  • The Pediatric Education Resources package is included with the Premium subscription offering for the SafeDose drug administration software suite.
  • The SafeDose Pediatric Education Resources include comprehensive simulation planners, quick visual in-service sheets, and brief videos on where to find further point-of-care and educational content within the SafeDose software.
  • This bundle includes access to the asthma section within the SafeDose software, asthma Readiness Resources, and asthma Education Resources.

Vivacelle Bio Integrates Sub-Saharan Africa Strategy into Series B Financing Round

Retrieved on: 
Thursday, February 22, 2024

Targeted $20M Series B Round to include Sub-Saharan Africa in product development.

Key Points: 
  • Targeted $20M Series B Round to include Sub-Saharan Africa in product development.
  • Vivacelle Bio is partnering with Propelevate to drive the Sub-Saharan Africa strategy, which is fully integrated into its Series B financing round.
  • Through partnership with Propelevate, Vivacelle Bio will engage global health funders and stakeholders during final stages of product development, and Propelevate will drive Vivacelle Bio's go-to-market strategy for African markets upon regulatory approval.
  • "We are excited to partner with Vivacelle Bio because of their commitment to Sub-Saharan Africa.

Regard and Kettering Health Hamilton Partner to Streamline EHR Navigation

Retrieved on: 
Thursday, February 22, 2024

LOS ANGELES, Feb. 22, 2024 /PRNewswire/ -- Regard, the leading AI clinical platform, announced a partnership today with Kettering Health Hamilton to implement their groundbreaking EHR-based technology that analyzes the entirety of the medical record and streamlines navigation for busy clinicians. The new partnership will allow for prevention of medical errors, time back for physicians, improved documentation quality, and better financial outcomes within the healthcare system.

Key Points: 
  • That's why we are excited to be partnering with the Regard team, innovators on the frontline of healthcare delivery," said Marcus Romanello, MD, Chief Medical Officer at Kettering Health Hamilton.
  • We look forward to the impact of this launch at Kettering Health Hamilton."
  • "We are thrilled to partner with Kettering Health Hamilton to help them meaningfully leverage our technology while working to empower the physicians within the hospital and improve patient care," said Nate Wilson, Co-founder and Chief Operating Officer at Regard.
  • "Over the next several years, we can't wait to see the significant impact this partnership will bring to the physicians and patients of Kettering Health Hamilton."

Public advisory - APO-Mometasone nasal spray: Two lots recalled due to possible risk of infection

Retrieved on: 
Monday, February 19, 2024

Apotex Inc. is recalling two lots of APO-Mometasone nasal spray due to possible bacterial contamination with Burkholderia cepacia complex (Bcc).

Key Points: 
  • Apotex Inc. is recalling two lots of APO-Mometasone nasal spray due to possible bacterial contamination with Burkholderia cepacia complex (Bcc).
  • APO-Mometasone nasal spray is a prescription drug used to treat seasonal and year-round nasal allergy symptoms (such as itchy, stuffy or runny nose and sneezing) in children 3-11 years old.
  • It is also used to treat sinusitis (sinus inflammation) in adults and children 12 years of age and older, and nasal polyps in adults.
  • The effects of Bcc vary widely, ranging from no symptoms at all to serious infections.

T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, February 15, 2024

LEXINGTON, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) --  T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced preliminary unaudited financial and operational results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • LEXINGTON, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) --  T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced preliminary unaudited financial and operational results for the fourth quarter and full year ended December 31, 2023.
  • Achieved full year 2023 total revenue of $7.2 million, including sepsis and related product revenue of $6.8 million and research and contribution revenue of $0.4 million.
  • Achieved fourth quarter 2023 total revenue of $1.7 million, comprised entirely of product revenue including record sales of the T2Bacteria Panel in the U.S.
  • Executed contracts for 26 T2Dx® Instruments in 2023, including 19 T2Dx Instruments from outside the U.S. and 7 T2Dx Instruments from the U.S.

T2 Biosystems Announces Commercial Expansion Through Distributors in Europe and Asia

Retrieved on: 
Thursday, February 15, 2024

Under the terms of the agreements, T2 Biosystems will sell the T2Dx® Instrument, the T2Bacteria® Panel, the T2Candida® Panel, and the T2Resistance® Panel into these countries through our distribution partners.

Key Points: 
  • Under the terms of the agreements, T2 Biosystems will sell the T2Dx® Instrument, the T2Bacteria® Panel, the T2Candida® Panel, and the T2Resistance® Panel into these countries through our distribution partners.
  • The execution of these territory exclusive distribution agreements further expands T2 Biosystems’ commercial business internationally.
  • Finally, T2 Biosystems’ current distribution partner Biomedica, which secured the company’s second largest T2Dx Instrument contract in company history during 2023 in Poland, is re-entering the Switzerland market with T2 Biosystems’ sepsis products.
  • "We are committed to expanding our commercialization worldwide and these new distribution agreements provide access to important markets in Europe and Asia,” said John Sperzel, Chairman and CEO of T2 Biosystems.